Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims about food/meal timing and administration setting are unsupported or not addressed in the provided label excerpts, which focus on risks (infections/TB/hypersensitivity/IBD/immunizations) and limited interaction guidance. Only the infection risk and general instruction to seek medical advice for infection signs are supported.
Category Scores
Accurate Statements
Cosentyx can increase the risk of infections.
5.1 Infections: "COSENTYX may increase the risk of infections."
Contact a clinician promptly if signs of infection occur while on Cosentyx, such as fever, persistent sore throat, cough, burning with urination, or new/worsening skin infections.
5.1 Infections: "Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur." (Specific examples like fever/sore throat/cough/dysuria/skin infections are not explicitly listed in the provided excerpts.)
Unsupported Statements
Cosentyx (secukinumab) is given by injection.
The provided label excerpts do not state route/form as injection.
Food does not change how Cosentyx works in the body.
No food/meal timing/pharmacokinetic statement is included in the provided excerpts.
Cosentyx can usually be taken with or without food.
No oral dosing/food instructions are included; also the provided label excerpts do not address food effects.
No special timing with meals is required for Cosentyx.
Not addressed in the provided excerpts.
Food is not expected to affect Cosentyx absorption.
Not addressed in the provided excerpts.
Food is not expected to affect Cosentyx absorption because Cosentyx is injected under the skin rather than taken as a pill by mouth.
The provided excerpts do not include food/absorption statements or support the route rationale as phrased.
Cosentyx is injected under the skin (or in a clinic setting depending on the dosing plan).
The provided excerpts do not specify subcutaneous route or clinic-setting administration.
The main practical side-effect concerns for Cosentyx are more about the medication itself (for example, infections) than about eating timing.
The provided excerpts do not discuss meal timing as a factor or compare practical side-effect concerns.
Meal timing does not change Cosentyx itself.
Not addressed in the provided excerpts.
There are no specific diet restrictions tied to Cosentyx that are universal.
Not addressed in the provided excerpts.
Contradictions
Important Omissions
Contraindication about previous serious hypersensitivity to secukinumab or excipients (and reports of anaphylaxis/angioedema) was not mentioned.
Importance:
Moderate
TB screening/evaluation and avoidance of Cosentyx in active TB; treat latent TB prior; monitor for TB during/after treatment.
Importance:
Moderate
Immunization guidance: consider completing vaccinations prior; avoid live vaccines.
Importance:
Moderate
Other key warnings/precautions relevant to safety (e.g., hypersensitivity actions, IBD exacerbations/monitoring, eczematous eruptions) were not mentioned.
Importance:
Moderate
Drug interaction monitoring for CYP450 substrates on initiation/discontinuation (consider monitoring and/or dosage adjustment).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Although infection risk and seeking advice for infection signs are supported, multiple claims about food/meal timing and administration are unsupported by the provided label excerpts. Missing safety-critical label topics (TB screening, hypersensitivity contraindication, immunizations/live vaccine avoidance) increases the chance of incomplete label-aligned counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Many statements (food effects/meal timing, absorption rationale, and administration details) are not supported by the provided FDA label excerpts; key label safety elements (TB evaluation, contraindication/hypersensitivity, live vaccine avoidance) are omitted.
Suggested Improvement
Limit claims to label-supported content from the provided excerpts (e.g., infection risk, instruction to seek advice for infection signs, hypersensitivity contraindication, TB evaluation, immunization/live vaccine guidance, and CYP450 interaction monitoring).